Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 19/20 | 0.84 |
| ▸ | SLC6A2 | P23975 | 16/20 | 0.84 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5190976 | 1.00 | SLC6A3 (0.84) | SLC6A3SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL15163018 | 0.99 | SLC6A3 (0.82) | SLC6A3SLC6A2SLC6A4 | |
| Pyrovalerone SCHEMBL164376 | 0.91 | SLC6A3 (1.00) | SLC6A3SLC6A2SLC6A4 | |
| Pyrovalerone SCHEMBL4930605 | 0.91 | SLC6A3 (1.00) | SLC6A3SLC6A2SLC6A4 | |
| Pyrovalerone SCHEMBL4929129 | 0.91 | SLC6A3 (1.00) | SLC6A3SLC6A2SLC6A4 | |
| Pyrovalerone SCHEMBL121638 | 0.90 | SLC6A3 (0.97) | SLC6A3SLC6A2SLC6A4 | |
| Pyrovalerone SCHEMBL1649739 | 0.89 | SLC6A3 (0.94) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL21271156 | 0.87 | SLC6A3 (0.83) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL27098434 | 0.86 | SLC6A3 (0.81) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL27098438 | 0.86 | SLC6A3 (0.81) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2626358-B1 | Immunoassay for pyrrolidinophenones | RANDOX LAB LTD (GB) | 2015-09-02 | — | — | EP | claimed |
| US-20150071861-A1 | POLYMER, CONTRAST AGENT FOR NUCLEAR MAGNETIC RESONANCE ANALYSIS OR MAGNETIC RESONANCE IMAGING USING THE POLYMER, COMPOUND AND METHOD OF NUCLEAR MAGNETIC RESONANCE ANALYSIS AND METHOD OF MAGNETIC RESONANCE IMAGING USING THE POLYMER | CANON KABUSHIKI KAISHA (JP) | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150071861-A1 | POLYMER, CONTRAST AGENT FOR NUCLEAR MAGNETIC RESONANCE ANALYSIS OR MAGNETIC RESONANCE IMAGING USING THE POLYMER, COMPOUND AND METHOD OF NUCLEAR MAGNETIC RESONANCE ANALYSIS AND METHOD OF MAGNETIC RESONANCE IMAGING USING THE POLYMER | PHOSPHO1, NPPA, NMRAL1 | SLC6A3 1299/4885SLC6A2 1399/4885SLC6A4 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.